Record: found
Abstract: not found
Article: not found

Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (BC): first- and second-line data from the BOLERO-4 study

Author(s): F. CARDOSO, C Villanueva, M Royce, F. CRUZ, M Debled, R. HEGG

Publication date: 2017

Read this article at

ScienceOpen

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Data availability:

ScienceOpen disciplines: Oncology & Radiotherapy, Medicine

Everolimus (EVE) plus endocrine therapy in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (BC): first- and second-line data from the BOLERO-4 study

Read this article at

Related collections

Karger: Oncology

Comments

Comment on this article

Similar content 1,815

Cited by 1